New drugs: golimumab, besifloxacin hydrochloride, and artemether/lumefantrine.
Hussar
Daniel A
DA
College of Pharmacy, University of the Sciences, Philadelphia, USA.
D000818:Animals; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000962:Antimalarials / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001381:Azepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D004983:Ethanolamines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005449:Fluorenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D016896:Treatment Outcome
D018927:Anti-Asthmatic Agents; D000890:Anti-Infective Agents; D000911:Antibodies, Monoclonal; D000962:Antimalarials; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins; D001381:Azepines; D004338:Drug Combinations; D004983:Ethanolamines; D005449:Fluorenes; D024841:Fluoroquinolones; C529000:golimumab; C522124:besifloxacin